Unicycive Therapeutics (UNCY) Competitors

Unicycive Therapeutics logo
$3.70 +0.15 (+4.23%)
Closing price 04:00 PM Eastern
Extended Trading
$3.73 +0.03 (+0.81%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UNCY vs. CTNM, TLRY, FENC, SPRY, and AVIR

Should you buy Unicycive Therapeutics stock or one of its competitors? Unicycive Therapeutics's main competitors and comparable companies include Contineum Therapeutics (CTNM), Tilray Brands (TLRY), Adherex Technologies (FENC), ARS Pharmaceuticals (SPRY), and Atea Pharmaceuticals (AVIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Unicycive Therapeutics compare to Contineum Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Contineum Therapeutics' return on equity of -25.48% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Unicycive TherapeuticsN/A -91.50% -61.47%
Contineum Therapeutics N/A -25.48%-24.28%

Unicycive Therapeutics presently has a consensus target price of $18.25, suggesting a potential upside of 393.24%. Contineum Therapeutics has a consensus target price of $21.40, suggesting a potential upside of 121.30%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Unicycive Therapeutics is more favorable than Contineum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Contineum Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Unicycive Therapeutics has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unicycive Therapeutics$680K151.54-$26.56M-$1.75N/A
Contineum Therapeutics$50M7.59-$59.98M-$1.77N/A

In the previous week, Unicycive Therapeutics had 5 more articles in the media than Contineum Therapeutics. MarketBeat recorded 8 mentions for Unicycive Therapeutics and 3 mentions for Contineum Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.58 beat Contineum Therapeutics' score of 0.58 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Unicycive Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Contineum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Unicycive Therapeutics has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

40.4% of Unicycive Therapeutics shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Unicycive Therapeutics beats Contineum Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Unicycive Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -16.91%. Tilray Brands' return on equity of -10.39% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-16.91% -10.39% -7.38%
Unicycive Therapeutics N/A -91.50%-61.47%

Tilray Brands currently has a consensus price target of $5.90, indicating a potential upside of 152.14%. Unicycive Therapeutics has a consensus price target of $18.25, indicating a potential upside of 393.24%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Tilray Brands.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
2 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.38
Unicycive Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Tilray Brands has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

Unicycive Therapeutics has lower revenue, but higher earnings than Tilray Brands. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray Brands$915.45M0.38-$121.40M-$1.40N/A
Unicycive Therapeutics$680K151.54-$26.56M-$1.75N/A

In the previous week, Tilray Brands had 7 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 15 mentions for Tilray Brands and 8 mentions for Unicycive Therapeutics. Tilray Brands' average media sentiment score of 0.62 beat Unicycive Therapeutics' score of 0.58 indicating that Tilray Brands is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tilray Brands
5 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Unicycive Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 1.6% of Tilray Brands shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Tilray Brands and Unicycive Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Adherex Technologies presently has a consensus target price of $17.25, suggesting a potential upside of 35.19%. Unicycive Therapeutics has a consensus target price of $18.25, suggesting a potential upside of 393.24%. Given Unicycive Therapeutics' higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Adherex Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adherex Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00
Unicycive Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

In the previous week, Adherex Technologies had 4 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 12 mentions for Adherex Technologies and 8 mentions for Unicycive Therapeutics. Adherex Technologies' average media sentiment score of 0.78 beat Unicycive Therapeutics' score of 0.58 indicating that Adherex Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adherex Technologies
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Unicycive Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Adherex Technologies has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Adherex Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adherex Technologies$44.64M10.07-$9.74M$0.011,276.00
Unicycive Therapeutics$680K151.54-$26.56M-$1.75N/A

Adherex Technologies has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

Adherex Technologies has a net margin of 2.52% compared to Unicycive Therapeutics' net margin of 0.00%. Adherex Technologies' return on equity of 9.58% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Adherex Technologies2.52% 9.58% 5.08%
Unicycive Therapeutics N/A -91.50%-61.47%

Summary

Adherex Technologies beats Unicycive Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Unicycive Therapeutics compare to ARS Pharmaceuticals?

Unicycive Therapeutics (NASDAQ:UNCY) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

In the previous week, Unicycive Therapeutics had 6 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 8 mentions for Unicycive Therapeutics and 2 mentions for ARS Pharmaceuticals. Unicycive Therapeutics' average media sentiment score of 0.58 beat ARS Pharmaceuticals' score of 0.40 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Unicycive Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
ARS Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Unicycive Therapeutics has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Unicycive Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -163.64%. Unicycive Therapeutics' return on equity of -91.50% beat ARS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Unicycive TherapeuticsN/A -91.50% -61.47%
ARS Pharmaceuticals -163.64%-453.93%-71.62%

Unicycive Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unicycive Therapeutics$680K151.54-$26.56M-$1.75N/A
ARS Pharmaceuticals$84.28M4.28-$171.30M-$2.02N/A

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Unicycive Therapeutics currently has a consensus target price of $18.25, suggesting a potential upside of 393.24%. ARS Pharmaceuticals has a consensus target price of $23.33, suggesting a potential upside of 549.95%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Unicycive Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
ARS Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Unicycive Therapeutics beats ARS Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Atea Pharmaceuticals' return on equity of -69.91% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atea PharmaceuticalsN/A -69.91% -61.22%
Unicycive Therapeutics N/A -91.50%-61.47%

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Unicycive Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/A-$158.35M-$1.95N/A
Unicycive Therapeutics$680K151.54-$26.56M-$1.75N/A

Atea Pharmaceuticals has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

In the previous week, Unicycive Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 8 mentions for Unicycive Therapeutics and 6 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.92 beat Unicycive Therapeutics' score of 0.58 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Atea Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Unicycive Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Atea Pharmaceuticals presently has a consensus price target of $8.00, suggesting a potential upside of 94.17%. Unicycive Therapeutics has a consensus price target of $18.25, suggesting a potential upside of 393.24%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Atea Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atea Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33
Unicycive Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Unicycive Therapeutics beats Atea Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UNCY vs. The Competition

MetricUnicycive TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$101.39M$13.75B$7.85B$12.17B
Dividend YieldN/A2.58%2.46%4.41%
P/E Ratio-2.1126.0432.9627.39
Price / Sales151.547.318.595.73
Price / CashN/A15.7421.9322.50
Price / Book2.625.144.403.70
Net Income-$26.56M$2.88B$3.52B$392.17M
7 Day PerformanceN/A-3.87%-5.34%-4.53%
1 Month Performance10.12%-3.96%-3.61%-5.86%
1 Year Performance-34.74%-7.13%0.01%-7.78%

Unicycive Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UNCY
Unicycive Therapeutics
2.6423 of 5 stars
$3.70
+4.2%
$18.25
+393.2%
-37.4%$101.39M$680KN/A22
CTNM
Contineum Therapeutics
1.796 of 5 stars
$10.39
+0.8%
$21.50
+107.0%
-7.5%$390.57M$50MN/A51
TLRY
Tilray Brands
3.4729 of 5 stars
$2.64
-7.5%
$5.90
+123.9%
-77.5%$389.43M$915.45MN/A3,595
FENC
Adherex Technologies
4.754 of 5 stars
$10.46
-3.4%
$17.00
+62.5%
+47.8%$368.82M$44.64MN/A35
SPRY
ARS Pharmaceuticals
2.3313 of 5 stars
$3.59
+14.0%
$23.33
+550.0%
-52.6%$357.52M$84.28MN/A200

Related Companies and Tools


This page (NASDAQ:UNCY) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners